TaiMed Biologics: Advancing Next-Generation HIV Therapies

TaiMed Biologics is a clinical-stage biopharmaceutical company specializing in the development and manufacturing of innovative biologics, with a core focus on HIV therapies.

The company’s flagship achievement is Trogarzo® (ibalizumab), the first monoclonal antibody approved for multidrug-resistant HIV. Trogarzo was approved by the U.S. FDA in 2018 and by the EMA in 2019, representing a life-saving therapy for patients with few remaining options. Today, it is commercialized in the U.S., EU, and other markets through partnerships, bringing meaningful benefit to patients worldwide.

Leveraging decades of antibody experience, TaiMed also provides end-to-end CDMO solutions, from early-stage development through commercial manufacturing, helping partners efficiently bring biologics to market.

Building on this foundation, TaiMed is advancing next-generation HIV antibodies, including the TMB-365/380 combination, which has recently achieved positive Phase 2a results and FDA Fast Track designation. In the Phase 2a study, the combination demonstrated robust antiviral efficacy with no predefined virologic failures observed during the treatment period. This next-generation therapy has the potential to deliver a longer-acting, more durable treatment option that avoids susceptibility testing requirements and represents the next chapter in TaiMed’s mission to transform HIV care.

In addition, TaiMed is expanding its discovery-stage efforts into antibody–drug conjugates (ADCs), an untapped modality for HIV therapy that could enable ultra–low-dose, long-acting regimens. This approach selectively delivers anti-HIV agents to CD4+ cells, the core HIV reservoir, achieving efficacy with less than 1% of the conventional therapeutic dose.

TaiMed is actively pursuing licensing and co-development opportunities around its de-risked TMB-365/380 program, the novel ADC platform, or potential combinations of TMB-365 with a partner’s molecule of choice.